Mark Holodniy, MD
Infectious Disease · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Holodniy’s office at (650) 852-3408 to ask if they take your plan before you enroll.
California Medical Board record
Licence G59492 · Current
Licensed to practise in California · since 1987 · expires 2028-10-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$23 in 2025
| 2025 | 1 | 1 | None | $23 |
| 2024 | 1 | 1 | None | $19 |
| 2023 | 1 | 1 | None | $17 |
| 2022 | 1 | 2 | None | $31 |
| 2021 | 1 | 5 | None | $85 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Alinity M | $23 | 1 payment
|
See the published payment
| Abbott Laboratories | Meals · 2025-06-06 | Alinity M | $23 |
See earlier years (2024, 2023, 2022, 2021)
2024: $19
| Abbott Laboratories | Alinity M | $19 | 1 payment
|
2023: $17
| Abbott Laboratories | Alinity M | $17 | 1 payment
|
2022: $31
| Abbott Laboratories | Alinity M | $31 | 2 payments
|
2021: $85
| Abbott Laboratories | Alinity M | $85 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 3 Placebocontrolled Randomized Observerblinded Study To Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older · 2019 | Their institution | $77,793 |
| PFIZER INC. · A Phase 3 Placebocontrolled Randomized Observerblinded Study To Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older · 2022 | Their institution | $15,600 |
| PFIZER INC. · A Phase 3 Placebocontrolled Randomized Observerblinded Study To Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older · 2020 | Their institution | $3,375 |
Professional record
- NPI
- 1073533238
- Licence
- CA G59492California G59492: Current · expires 2028-10-31
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 3801 Miranda Ave, Mail Code 132, Palo Alto, CA, 94304
- NPI first listed
- 2006-07-20
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.